<DOC>
	<DOCNO>NCT00194012</DOCNO>
	<brief_summary>The purpose study test effectiveness tolerability/safety aripiprazole ( abilify ) child subsyndromal symptom bipolar disorder also bipolar parent family member mood disorder .</brief_summary>
	<brief_title>Study Aripiprazole ( Abilify ) Versus Placebo Children With Subsyndromal Bipolar Disorder</brief_title>
	<detailed_description>This double-blind , placebo-controlled , parallel-arm , randomized clinical trial last 12 week . This placebo-controlled portion follow 6-week open label extension/stabilization phase . In order eligible participation extension/stabilization phase , subject must : 1 ) investigator 's opinion dose-limiting side effect likely attributable aripiprazole ( APZ ) ; 2 ) participate blinded portion clinical trial minimum 4 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Outpatients age 517 year ( inclusive ) Patients , investigator 's opinion substantial symptom mania , depression , within past 2 week treatment pharmacological agent warrant Currently meet Diagnostic Statistical Manual Mental Disorders ( DSMIV ) criteria either cyclothymia , bipolar disorder otherwise specify ( BP NOS ) base result semistructured diagnostic research assessment , Present Lifetime Version ( KSADSPresent Lifetime ( PL ) supplement section WASHU KSADS ) ( Geller et al. , 2001 ; Kaufman et al. , 1997 ) clinical interview child adolescent psychiatrist . Offspring parent bipolar spectrum disorder ( base result either Mini International Neuropsychiatric Interview ( MINI ) ( Sheehan et al. , 1998 ) Family History Method ( FHRDC ) ( Andreasen et al. , 1977 ) Has another first second degree relative mood disorder determine result either MINI FHRDC Has participate least 4 session psychotherapy specifically focused symptoms/management pediatric mood disorder continue clinically significant symptomatology Patients history intolerance APZ dose 0.1mg/kg/day Patients experience manic episode document treatment APZ monotherapy dose 0.2 mg/kg/day Patients active neurological/medical disorder treatment APZ would contraindicate Patients clinical evidence autistic disorder , Asperger 's disorder , Rett 's syndrome pervasive developmental disorder Patients clinical evidence mental retardation Patients know allergic hypersensitive aripiprazole Patients unable swallow pills/capsules Patients need hospitalization course study appear likely Patients start new psychotherapeutic intervention within less 4 week randomization Patients general medical neurological condition ( include clinically significant abnormality screen laboratory ) may consider etiology patient 's mood disorder Patients general medical neurological condition treatment atypical antipsychotic would contraindicate ( e.g . tardive dyskinesia ) Patients general medical neurological condition could interfere interpretation clinical response APZ treatment Patients take psychotropic agent ( psychostimulants ) within one week baseline ( 2 week fluoxetine ; 3 day psychostimulants ) Patients suicide attempt require medical/psychiatric care within past 6 month Has meet DSMIV criterion drug/alcohol abuse dependence within past 6 month Females currently pregnant lactate Sexually active female , investigator ' opinion use adequate form birth control</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>bipolar disorder</keyword>
</DOC>